Skip to main content
Anjana Pillai on Muck Rack

Anjana Pillai

As seen in: Nature, Wiley Online Library, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Journal of Medical Case Reports, FT Sri Lanka, Branding in Asia, CURE Magazine, OncLive, Campaign India and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anjana

Contact Anjana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement

|
By Josep M Llovet, Ezequiel Mauro, Lorenza Rimassa, Vincenzo Mazzaferro, Matthias Pinter, Robin Kate Kelley, Stephen Chan, Laura Kulik, Anjana Pillai, Lewis Roberts, Bruno Sangro, Teresa Casanovas, DAVID KAPLAN, Arndt Vogel, Mark Yarchoan, Richard Finn, Tim Meyer, Amit Singal
| Nature Verified
Abstract The management of hepatocellular carcinoma (HCC) has undergone radical change over the past decade. Immunotherapies now dominate the treatment of advanced-stage disease and are increasingly being evaluated in perioperative and intermediate-stage settings. However, in some instances, positive phase III trials have not translated into adoption by guidelines or regulatory agencies, highlighting the need to harmonize and update the current standards for trial design and end points.
Open in Who Shared Issue with article?

Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma

|
By Sarah Park, Andrew Davis Verified, Anjana Pillai
| JAMA: Journal of the American Medical Association Verified
Guideline title AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma Release date December 1, 2023 Developer and funding source American Association for the Study of Liver Diseases (AASLD) Target population Patients with high risk factors for hepatocellular carcinoma (HCC), such as cirrhosis of any etiology, chronic liver diseases most commonly due to chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, alcohol-associated liver disease,...
Open in Who Shared Issue with article?

Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma?

|
By Jennifer Wang, Anjana Pillai
| Wiley Online Library Verified
INVITED EDITORIAL Jennifer Wang, Jennifer Wang Division of Gastroenterology and Hepatology, Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA Search for more papers by this author Anjana A. Pillai, Corresponding Author Anjana A.
Open in Who Shared Issue with article?
See all 7 licensed articles (46 Total)